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Recent publications showed that the kinase MTOR localizes to lysosomes 
and its activation depends on amino 
acids inside the lysosomal lumen, imply-
ing that autophagic protein degradation 
is a positive regulator of MTOR in this 
setting. Since decreased MTOR activ-
ity results in autophagy induction, drug 
treatments that block autolysosomal deg-
radation (a commonly used technique to 
estimate autophagic flux) may actually 
interfere not only with lysosomal break-
down, but also increase autophagosome 
generation through impaired MTOR 
signaling.
Autophagy ensures the autophagosome-
mediated transport of cytoplasmic mate-
rial to lysosomes for degradation and 
re-use. By now it has become widely 
accepted that analyzing the number of 
autophagy-related structures alone is an 
inadequate measure of autophagic degra-
dation activity (flux), as increased auto-
phagosome numbers can reflect both 
their accelerated generation or decreased 
clearence. Similarly, the number and size 
of autolysosomes depend on both ’input’: 
material delivered by autophagosomes, and 
’output’: material degraded and recycled 
back to the cytoplasm for re-use. The lev-
els of activated, lipidated Atg8/MAP1LC3 
family proteins (mostly referred to as 
Atg8-II or LC3-II) are increased during 
autophagy induction which can be easily 
followed in western blot experiments, but 
since Atg8 molecules linked to the inner 
autophagosomal membrane are subject 
to degradation in autolysosomes, their 
levels also depend on both activation (i.e. 
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autophagy induction) and degradation 
(i.e. breakdown in autolysosomes).1
One popular method for the estima-
tion of autophagic flux is to carry out 
experiments in the absence and presence 
of lysosomal protease inhibitors (such as 
leupeptin), intralysosomal pH neutraliz-
ing agents (such as chloroquine), or drugs 
that inhibit the vacuolar type H+-ATPase 
(v-ATPase) complex necessary for lyso-
somal acidification (such as bafilomycin 
A
1
). These treatments block autopha-
gic degradation at a step downstream of 
autophagosome formation, allowing one 
to make a direct comparison of autopha-
gosome numbers or lipidated Atg8/LC3 
levels with experiments done without 
using these drugs.1
MTOR (mechanistic target of rapamy-
cin) is a serine/threonine kinase that inte-
grates multiple signals such as growth 
factor abundance with intracellular amino 
acid and ATP levels to coordinate cell 
growth and autophagy. MTOR promotes 
translation in a number of ways including 
the activation of RPS6KB1/2 (ribosomal 
protein S6 kinase, 70 kDa, polypep-
tide 1/2) and inhibition of EIF4EBP1 
(eukaryotic translation initiation fac-
tor 4E binding protein 1) and blocks 
autophagy by inhibiting the Atg1/ULK1 
(unc-51-like kinase 1) kinase complex.2 
MTOR is rapidly inactivated upon star-
vation that results in autophagy induction 
typically peaking at 2–4 h depending on 
the experimental system. Recent papers 
showed that autophagy is required for the 
re-activation of MTOR and repression of 
autophagy during prolonged starvation, 
and that amino acids inside lysosomes 
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Therefore, estimating MTOR activity by 
looking at phospho-RPS6KB1/2 and phos-
pho-EIF4EBP1 levels should be an essential 
part of flux assays that involve these drug 
treatments. Along these lines, finding of a 
drug or genetic mutation that specifically 
blocks only the fusion of autophagosomes 
with endosomes or lysosomes and not other 
vesicle fusion events would provide a useful 
tool for the autophagy community.
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are necessary for MTOR activity.3,4 Also, 
the ragulator complex required for amino 
acid-induced MTOR activation recruits 
MTOR complex 1 to the v-ATPase com-
plex and ensures the localization of active 
MTOR on lysosomes (Fig. 1A).5
In light of these new results, we may 
need to re-evaluate the use of inhibitors 
that block lysosomal protein degradation 
for autophagic flux. Bafilomycin, chloro-
quine and protease inhibitor treatments 
are very likely to interfere with MTOR 
activity, potentially resulting in further 
acceleration of autophagosome formation 
unless MTOR is already completely inac-
tive in the experimental setting (Fig. 1B). 
Figure 1. schematic representation of the connection between autophagy and mtor signal-
ing mediated by lysosomes. (A) induction of autophagy results in autophagosome-mediated 
delivery of proteins to lysosomes. the v-AtPase complex ensures optimal acidic pH for lysosomal 
proteases that break down proteins into amino acids, which in turn activate mtor complex 1 
associated with the v-AtPase complex. mtorC1 activation then results in feedback inhibition 
of autophagosome generation. (B) inhibition of the v-AtPase proton pump, neutralization of 
lysosomal acidity or block of lysosomal proteases decreases autophagic protein degradation and 
intralysosomal amino acid levels, likely leading to mtorC1 inactivation and increased formation 
of autophagosomes.
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